The Prioritization of Variants into Tiers is based on the Standards and Guidelines of the AMP.
Variants in Tier 1 are described as therapeutic, diagnostic or prognostic biomarkers
with an Evidence Level of A or B in at least one of the queried Knowledgebases.
The Prioritization of Variants into Tiers is based on the Standards and Guidelines of the AMP.
Variants in Tier 2 are described as therapeutic, diagnostic or prognostic biomarkers
with an Evidence Level of C or D in at least one of the queried Knowledgebases.
The Prioritization of Variants into Tiers is based on the Standards and Guidelines of the AMP.
Variants in Tier 3 are not necessarily described with therapeutic, diagnostic or prognostic evidence.
If so, the CIViC evidence level is E.
Other variants in Tier 3 are considered oncogenic in the CGI Knowledgebase
and are not observed at a significant allele frequency in the general population.